These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 25833957)

  • 1. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
    Burnett AK; Russell NH; Hills RK; Kell J; Cavenagh J; Kjeldsen L; McMullin MF; Cahalin P; Dennis M; Friis L; Thomas IF; Milligan D; Clark RE;
    Blood; 2015 Jun; 125(25):3878-85. PubMed ID: 25833957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
    Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
    J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daunorubicin 90 mg/m
    Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
    Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
    Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline dose intensification in acute myeloid leukemia.
    Fernandez HF; Sun Z; Yao X; Litzow MR; Luger SM; Paietta EM; Racevskis J; Dewald GW; Ketterling RP; Bennett JM; Rowe JM; Lazarus HM; Tallman MS
    N Engl J Med; 2009 Sep; 361(13):1249-59. PubMed ID: 19776406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
    Röllig C; Kramer M; Gabrecht M; Hänel M; Herbst R; Kaiser U; Schmitz N; Kullmer J; Fetscher S; Link H; Mantovani-Löffler L; Krümpelmann U; Neuhaus T; Heits F; Einsele H; Ritter B; Bornhäuser M; Schetelig J; Thiede C; Mohr B; Schaich M; Platzbecker U; Schäfer-Eckart K; Krämer A; Berdel WE; Serve H; Ehninger G; Schuler US;
    Ann Oncol; 2018 Apr; 29(4):973-978. PubMed ID: 29390048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
    Burnett AK; Russell NH; Hills RK; Kell J; Nielsen OJ; Dennis M; Cahalin P; Pocock C; Ali S; Burns S; Freeman S; Milligan D; Clark RE
    Leukemia; 2017 Feb; 31(2):310-317. PubMed ID: 27624670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 60 and 80 mg/m
    Vaezi M; Bahar B; Mousavi A; Yaghmai M; Kasaeian A; Souri M; Jahani M; Alimoghaddam K; Ghavamzadeh A
    Hematol Oncol; 2017 Mar; 35(1):101-105. PubMed ID: 26386260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
    Knapper S; Russell N; Gilkes A; Hills RK; Gale RE; Cavenagh JD; Jones G; Kjeldsen L; Grunwald MR; Thomas I; Konig H; Levis MJ; Burnett AK
    Blood; 2017 Mar; 129(9):1143-1154. PubMed ID: 27872058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
    Choi EJ; Lee JH; Lee JH; Park HS; Ko SH; Hur EH; Moon J; Goo BK; Kim Y; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
    Leuk Res; 2018 May; 68():51-56. PubMed ID: 29544132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
    Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
    J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
    Burnett A; Cavenagh J; Russell N; Hills R; Kell J; Jones G; Nielsen OJ; Khwaja A; Thomas I; Clark R;
    Haematologica; 2016 Jun; 101(6):724-31. PubMed ID: 26921360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.
    Luskin MR; Lee JW; Fernandez HF; Abdel-Wahab O; Bennett JM; Ketterling RP; Lazarus HM; Levine RL; Litzow MR; Paietta EM; Patel JP; Racevskis J; Rowe JM; Tallman MS; Sun Z; Luger SM
    Blood; 2016 Mar; 127(12):1551-8. PubMed ID: 26755712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose daunorubicin in older patients with acute myeloid leukemia.
    Löwenberg B; Ossenkoppele GJ; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Maertens J; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; van Marwijk Kooy M; Verdonck LF; Beck J; Döhner H; Gratwohl A; Pabst T; Verhoef G; ; ;
    N Engl J Med; 2009 Sep; 361(13):1235-48. PubMed ID: 19776405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
    Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
    Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
    Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
    J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
    Zeidner JF; Lee DJ; Frattini M; Fine GD; Costas J; Kolibaba K; Anthony SP; Bearss D; Smith BD
    Clin Cancer Res; 2021 Jan; 27(1):60-69. PubMed ID: 32998965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.